JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on TVRD stock, giving a Buy rating on November 14.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Debanjana Chatterjee’s rating is based on several key factors related to Tvardi Therapeutics’ recent developments and future prospects. The company has shared its third-quarter results for 2025 and outlined significant upcoming catalysts expected in the first half of 2026. These include the anticipated Phase 1b/2 trial and the results from the healthy volunteer study of their next-generation STAT3 inhibitor, TTI-109.
The management has provided insights into mitigating the diarrhea risk associated with TTI-109, which is expected to have a lower diarrhea liability due to its minimal excipient requirement, achieving high oral bioavailability in preclinical studies. Despite the disappointing outcome from the TTI-101 Phase 2 IPF study, the stock is trading near cash, and the low expectations from the upcoming data catalysts present a positive risk-reward scenario through the first half of 2026. This combination of factors has led to the reaffirmation of a Buy rating, albeit with a revised price target of $12.
Chatterjee covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Opus Genetics, and KalVista Pharmaceuticals. According to TipRanks, Chatterjee has an average return of 31.8% and a 64.13% success rate on recommended stocks.
In another report released on November 14, BTIG also maintained a Buy rating on the stock with a $15.00 price target.